Virginia 2022 Regular Session Status: Passed Senate

SB 772 — Cannabis; definitions, dispensing products, patient registration.

Last action — Left in Health, Welfare and Institutions

Track this bill free

No card. One bill, free forever — alerts when it moves.

  1. ✓
    Introduced
  2. ✓
    In Committee
  3. 3
    Passed Senate
  4. 4
    Passed House of Delegates
  5. 5
    To Executive
  6. 6
    Enacted

This bill died with 2022 Regular Session. It reached “Passed Senate” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.

This bill is no longer active — its legislative session has ended, so there is no live prognosis. It would have to be reintroduced in the current session to move again.

Summary

Board of Pharmacy; cannabis registration. Eliminates the Board of Pharmacy patient registration requirement for medical cannabis. The bill maintains the requirement that patients obtain a written certification from a health care provider to obtain medical cannabis.

Bill Text

What changed in the latest version

269 added · 280 removed

Plain-language change summary

The amendments to SB 772 include clarifications to the definitions of "cannabis oil" and "cannabis product," specifying the requirements for how cannabis oil can be formulated and what it includes. The term "designated caregiver facility" was also added, defining specific types of facilities that provide pharmaceutical services. These changes clarify how cannabis products are regulated and expand the definition of facilities that can assist patients, which could impact access to cannabis-based treatments.

→
Previous
Latest
SESSION LEGISLATION NOT PREPARED BY DLS INTRODUCED 22104985D I SENATE BILL NO.
SESSION SENATE SUBSTITUTE 22106018D SENATE BILL NO.
772 Offered January 21, 2022 N A BILL to amend and reenact §§ 54.1-3408.3, 54.1-3442.5, 54.1-3442.6 and 54.1-3442.7 of the CodT of Virginia, relating to the Board of Pha––––––––––nabis registration.
772 AMENDMENT IN THE NATURE OF A SUBSTITUTE (Proposed by the Senate Committee on Education and Health on February 10, 2022) (Patron Prior to Substitute––Senator Marsden) A BILL to amend and reenact §§ 54.1-3408.3, 54.1-3442.5, 54.1-3442.6, and 54.1-3442.7 of the Code of Be it enacted by the General Assembly of Virginia:nnabis products;
R Patron––Marsden –––––––––– O Referred to Committee on Education and Health D –––––––––– Be it enacted by the General Assembly of Virginia:
patient registration.
U 1.
1.
That §§ 54.1-3408.3, 54.1-3442.5, 54.1-3442.6 and 54.1-3442.7 of the Code of Virginia are C amended and reenacted as follows:
That §§ 54.1-3408.3, 54.1-3442.5, 54.1-3442.6, and 54.1-3442.7 of the Code of Virginia are amended and reenacted as follows:
§ 54.1-3408.3.
Certification for use of cannabis oil for treatment.
As used in this section:n for use of cannabis oil for treatment.
As used in this section:
E "Botanical cannabis" means cannabis that is composed wholly of usable cannabis from the same parts of the same chemovar of cannabis plant.
of the same chemovar of cannabis plant.that is composed wholly of usable cannabis from the sameSparts "Cannabis oil" means any formulation of processed Cannabis plant extract, which may include oil from industrial hemp extract acquired by a pharmaceutical processor pursuant to § 54.1-3442.6, or a dilution of the resin of the Cannabis plant that contains at least five milligrams of cannabidiol (CBD) or tetrahydrocannabinolic acid (THC-A) and no more than 10 milligrams of delta-9-tetrahydrocannabinol per dose.
"Cannabis oil" means any formulation of processed Cannabis plant extract, which may include oil from industrial hemp extract acquired by a pharmaceutical processor pursuant to § 54.1-3442.6, or a dilution of the resin of the Cannabis plant that contains at least five milligrams of cannabidiol (CBD) or tetrahydrocannabinolic acid (THC-A) and no more than 10 milligrams of delta-9-tetrahydrocannabinol per dose.
unless it has been acquired and formulated with "Cannabis product" means a product that is (i) produced by a pharmaceutical processor, registered with the Board, and compliant with testing requirements and (ii) composed of cannabis oil or botanical cannabis.
unless it has been acquired and formulateA with "Cannabis product" means a product that is (i) produced by a pharmaceutical processor, regisTered with the Board, and compliant with testing requirements and (ii) composed of cannabis oil or botanical cannabis.
2 "Designated caregiver facility" means any hospice or hospice facility licensed pursuant to § 32.1-162.3, or home care organization as defined in § 32.1-162.7 that provides pharmaceutical services or home health services, private provider licensed by the Department of Behavioral Health and Developmental Services pursuant to Article 2 (§ 37.2-403 et seq.) of Chapter 4 of Title 37.2, assisted § 63.2-1701.ity licensed pursuant to § 63.2-1701, or adult day care center licensed pursuant to "Practitioner" means a practitioner of medicine or osteopathy licensed by the Board of Medicine, a physician assistant licensed by the Board of Medicine, or a nurse practitioner jointly licensed by the Board of Medicine and the Board of Nursing.
E "Designated caregiver facility" means any hospice or hospice facility licensed pursuant to § 32.1-162.3, or home care organization as defined in § 32.1-162.7 that provides pharmaceutical services Developmental Services pursuant to Article 2 (§ 37.2-403 et seq.) of Chapter 4 of Title 37.2, assisted living facility licensed pursuant to § 63.2-1701, or adult day care center licensed pursuant toS § 63.2-1701.
35 "Registered agent" means an individual designated by a patient who has been issued a written 36 certification, or, if such patient is a minor or an incapacitated adult as defined in § 18.2-369, designated 37 by such patient's parent or legal guardian, and registered with the Board pursuant to subsection G.
U "Practitioner" means a practitioner of medicine or osteopathy licensed by the Board of MedicBne, a physician assistant licensed by the Board of Medicine, or a nurse practitioner jointly licensed by the Boa"Registered agent" means an individual designated by a patient who has been issued a writtenS certification, or, if such patient is a minor or an incapacitated adult as defined in § 18.2-369, designated 36 by such patient's parent or legal guardian, and registered with the Board pursuant to subsection G.
38 "Usable cannabis" means any cannabis plant material, including seeds, but not (i) resin that has been from the stalks, or any other compound, manufacture, salt, or derivative, mixture, or preparation of theoduced mature stalks;
37 "Usable cannabis" means any cannabis plant material, including seeds, but not (i) resin that has been 38 extracted from any part of the cannabis plant, its seeds, or its resin;
or (iii) oil or cake made from the seeds of the plant.
(ii) the mature stalks,Tfiber produced 39 from the stalks, or any other compound, manufacture, salt, or derivative, mixture, or preparatiUn of the matB.
B.
A written certification shall not be issued to a patient by more than one practitioner during any given time period.
A written certification shall Eot be issued to a patient by more than one practitioner during any given time period.
The practitioner shall use his professional judgment to determine the manner and frequency of patient care and evaluation and may employ the use of telemedicine, provided that the use of telemedicine includes the delivery of consistent with the standard of care to dispense botanical cannabis to a minor, the written certification shall specifically authorize such dispensing.
The practitioner shall use his professional judgment to determine the manner and frequency of patient care and evaluation and patient care through real-time interactive audio-visual technology.
If a practitioner determines it is consistent with the standard of care to dispense botanical cannabis to a minor, the written certification shall specifically authorize such dispensing.
C.
S C.
The written certification shall be on a form provided by the Office of the Executive Secretary of the Supreme Court developed in consultation with the Board of Medicine.
The written certification shall be on a form provided by the Office of the Executive Secr7tary of shall contain the name, address, and telephone number of the practitioner, the name and address of the patient issued the written certification, the date on which the written certification was made, and the signature or authentic electronic signature of the practitioner.
Such written certification shall contain the name, address, and telephone number of the practitioner, the name and address of the patient issued the written certification, the date on which the written certification was made, and the to subsection B shall expire no later than one year after its issuance unless the practitioner provides int SB772 2 of 5 such written certification an earlier expiration.
Such written certification issued pursuant to subsection B shall expire no later than one year after its issuance unless the practitioner provides in such written certification an earlier expiration.
No practitioner shall be prosecuted under § 18.2-248 or 18.2-248.1 for the issuance of a certification for the use of cannabis products for the treatment or to alleviate the symptoms of a patient's diagnosed condition or disease pursuant to a written certification issued pursuant to subsection B.
No practitioner shall be prosecuted under § 18.2-248 or 18.2-248.1 for the issuance of a SB772S1 2 of 5 certification for the use of cannabis products for the treatment or to alleviate the symptoms of a patient's diagnosed condition or disease pursuant to a written certification issued pursuant to subsection B.
JI.
J.
ARTICLE 4.2.
PERMITTING OF PHARMACEUTICAL PROCESSORS TO PRODUCE AND DISPENSE CANNABIS PRODUCTS.
"Pharmaceutical processor" means a facility that (i) has obtained a permit from the Board pursuant to § 54.1-3408.3 and (ii) cultivates Cannabis plants intended only for the production of cannabis oil, botanical cannabis, and usable cannabis, produces cannabis products, and dispenses cannabis products to of 5 a registered patient pursuant to a written certification, his registered agent, or, if such patient is a minor or an incapacitated adult as defined in § 18.2-369, such patient's parent or legal guardian.
"Pharmaceutical processor" means a facility that (i) has obtained a permit from the Board pursuant to § 54.1-3408.3 and (ii) cultivates Cannabis plants intended only for the production of cannabis oil, botanical cannabis, and usable cannabis, produces cannabis products, and dispenses cannabis products to a registered patient, pursuant to a written certification, his registered agent, or, if such patient is a minor or an incapacitated adult as defined in § 18.2-369, such patient's parent or legal guardian.
I "Practitioner" has the same meaning as specified in § 54.1-3408.3.
"Practitioner" has the same meaning as specified in § 54.1-3408.3.
N 2017, c.
"Registered agent" has the same meaning as specified in § 54.1-3408.3.
613;
of 5 A.
2018, cc.
No person shall operate a pharmaceutical processor or a cannabis dispensing facility without first obtaining a permit from the Board.
246, 809;
2019, c.
690;
2020, c.
1278;
2021, Sp.
Sess.
I, cc.
205, 227, 228.
Show all 110 changed rows (70 more)
Previous
Latest
§ 54.1-3442.6.
Permit to operate pharmaceutical processor or cannabis dispensing facility.
T A.
No person shall operate a pharmaceutical processor or a cannabis dispensing facility withRut first obtaining a permit from the Board.
The Board shall establish an appliDation fee and other general requirements for such application.
The Board shall establish an application fee and other general requirements for such application.
Permits shall be displayed in a conspicuous place on the premises of the pharmaceutical processEr and cannabis dispensing facility.
Permits shall be displayed in a conspicuous place on the premises of the pharmaceutical processor and cannabis dispensing facility.
The Board shall adopt regulations establishing health, safety, and security requirements for pharmaceutical processors and cannabis dispensing facilities.
The Board shall adopt regulations establishing health, safety, and security requirements for for (i) physical standards;
Such regulations shall include requirements for (i) physical standards;
(iv) minimum cannabis product and the amounts recommended by the practitioner or dispensing pharmacist, andical packaging;
(iv) minimum equipment and resources;
(v) recordkeeping;
(vi) labeling, including the potency of each botanical cannabis product and the amounts recommended by the practitioner or dispensing pharmacist, and S packaging;
(viii) processes for safely and securely dispensing and delivering in person cannabis products to a registered patient, his registered agent, or, if such patient is a minor or an incapacitated adult as defined in § 18.2-369, such patient's parent or legal guardian;
(viii) processes for safely and securely dispensing and delivering in person cannabis products to a registered patient, his registered parent or legal guardian;
(ix) dosage limitations for cannabis oil that provide that each dispeSsed dose of cannabis oil not exceed 10 milligrams of delta-9-tetrahydrocannabinol;
(ix) dosage limitations for cannabis oil that provide that each dispeNsed dose of cannabis oil not exceed 10 milligrams of delta-9-tetrahydrocannabinol;
(x) a process for the wh7lesale distribution of and the transfer of usable cannabis, botanical cannabis, cannabis oil, and cann2bis dispensing facility, and between cannabis dispensing facilities;
(x) a process for the wholesale distribution of and the transfer of usable cannabis, botanical cannabis, cannabis oil, and cannAbis products between pharmaceutical processors, between a pharmaceutical processor and a cannabis dispensing facility, and between cannabis dispensing facilities;
(xi) an allowance for the sale of devices for administration of dispensed cannabis products and hemp-based CBD products that meet the applicable standards set forth in state and federal law, including the laboratory testing standards set forth in subsection M;
(xi) an allowance for the saleTof devices applicable standards set forth in state and federal law, including the laboratory testing standards set forth in subsection M;
(xiii) a process for acquiring oil from industrial hemp extract and formulating such oil extract with and promotion of the pharmaceutical processor's products and operations, which shall not limit thertising pharmaceutical processor from the provision of educational material to practitioners who issue written certifications and registered patients.
(xiii) a process for acquiring oil from industrial hemp extract and formulating such oil extracS with and promotion of the pharmaceutical processor's products and operations, which shall not limit thertising pharmaceutical processor from the provision of educational material to practitioners who issue written certifications and registered patients.
The Board shall also adopt regulations for pharmaceutical processors that include requirements for (a) processes for safely and securely cultivating Cannabis plants intended for producing cannabis products, (b) the secure disposal of agricultural waste, and (c) a process for registering cannabis oil products.
The Board shall also adopt regulations for pharmaceutical processors that include requirements for (a) processes for safely and securely cultivating CannSbis plants intended for producing cannabis products, (b) the secure disposal of agricultural waste, and (c) a process forD.
D.
The Board shall require that, after processing and before dispensing any cannabis products, a pharmaceutical processor shall make a sample available from each batch of cannabis product for testing by an independent laboratory located in Virginia meeting Board requirements.
The Board shall require that, after processing and before dispensing any cannabis products, a by an independent laboratory located in Virginia meeting Board requirements.
A valid sample sizT for testing shall be determined by each laboratory and may vary due to sample matrix, analytical method, and laboratory-specific procedures.
A valid sample size forng testing shall be determined by each laboratory and may vary due to sample matrix, analytical method, and laboratory-specific procedures.
A minimum sample size of 0.5 percent of individual units for representative cannabis oil sample for analysis.
A minimum sample size of 0.5 percent of individual units for dispensing or distribution from each homogenized batch of cannabis oil is required to achieve a representative cannabis oil sample for analysis.
A minimum sample size, to be determined by theT certified testing laboratory, from each batch of botanical cannabis is required to achieve a reEresentative botanical cannabis sample for analysis.
A minimum sample size, to be determined by the certified testing laboratory, from each batch of botanical cannabis is required to achieve a representative botanical cannabis sample for analysis.
Botanical cannabis products shall only be tested for the following:
Botanical cannabis products shall only be tested for the residue;
total cannabidiol (CBD);
total tetrahydrocannabinol (THC);
terpenes;
pesticide chemical residue;
Testing thresholds shall be consistent with generally accepted cannabis industry thresholds.
Testing thresholds shall remediate cannabis oil that fails any quality testing standard.
The pharmaceutical processor may remediate cannabis oil that fails any quality testing standard.
If the batch fails retesting, it shall be considered usable cannabis and may be processed into cannabis oil, unless the failure is related to pesticide requirements, in which case the batch shall not be considered usable cannabis and shall not be processed into cannabis oil.
If the batch fails retesting, it shall be considered usable cannabis and may be processed into cannabis oil, unless the failure is related to pesticide requirements, inSwhich case the batch shall not be considered usable cannabis and shall not be processed into cannabis oil.7Stability pharmaceutical processor of six months or less from the date of packaging.ion date assigned by 2he E.
Stability pharmaceutical processor of six months or less from the date of packaging.ion date assigned by the SB772 4 of 5 E.
A laboratory testing samples for a pharmaceutical processor shall obtain a controlled sub1tances registration certificate pursuant to § 54.1-3423 and shall comply with quality standards established by the Board in regulation.
A laboratory testing samples for a pharmaceutical processor shall obtain a controlled substances registration certificate pursuant to § 54.1-3423 and shall comply with quality standards established by the Board in regulation.
Every pharmaceutical processor's dispensing area or cannabis dispensing facility shall be under the personal supervision of a licensed pharmacist on the premises of the pharmaceutical processor or cannabis dispensing facility.
Every pharmaceutical processor's dispensing area or cannabis dispensing facility shall be under the personal supervision of a licensed pharmacist on the premises of the pharmaceutical processor or SB772S1 4 of 5 cannabis dispensing facility.
A pharmaceutical processor may process and formulate such oil extract with cannabis plant extract into an allowable dosage of cannabis oil.
A pharmaceutical processor may process and formulate such extract with cannabis plant extract into an allowable dosage of cannabis oil.
The legislative review provisions of of 5 subsections A and B of § 2.2-4014 shall apply to the promulgation or final adoption process for regulations pursuant to this section.
The legislative review provisions of subsections A and B of § 2.2-4014 shall apply to the promulgation or final adoption process for regulations pursuant to this section.
The Board of Pharmacy shall consider and keep on file allIpublic comO.
The Board of Pharmacy shall consider and keep on file all public comments received for any regulation adopted pursuant to this section.
O.
2017, c.
§ 54.1-3442.7.
613;
2018, c.
567;
2019, cc.
417, 681, 690;
2020, cc.
831, 928, 944, 1278;
2021, Sp.
Sess.
I, cc.
205, 227, 228, 550, 551.
T § 54.1-3442.7.
R A.
of 5 A.
A pharmaceutical processor or cannabis dispensing facility shall dispense or deliver cannObis products only in person to (i) a patient who is a Virginia resident or temporarily resides in Virginia as Board pursuant to § 54.1-3408.3;
A pharmaceutical processor or cannabis dispensing facility shall dispense or deliver cannabis products only in person to (i) a patient who is a Virginia resident or temporarily resides in Virginia as made evident to the Board, and has been issued a valid written certification, and is registered with the an incapacitated adult as defined in § 18.2-369, such patient's parent or legal guardian who is a Virginia or resident or temporarily resides in Virginia as made evident to the Board and is registered with the Board pursuant to § 54.1-3408.3.
(ii) such patient's registered agent;
A companion may accompany a registered patient into a pharmaceutical processor's dispensing area or cannabis dispensing facility.
or (iii) if such patient is a minor or an incapacitated adult as defined in § 18.2-369, such patient's parent or legal guardian who isUa Virginia resident or temporarily resides in Virginia as made evident to the Board and is registered with the Board pursuant to § 54.1-3408.3.
Prior to the initial dispensing of cannabis oil pharmaceutical processor or cannabis dispensing facility shall make and maintain, on site or remotely by electronic means, for two years a paper or electronic copy of the written certification that provides an exact image of the document that is clearly legible;
A companion may accompany a registered patient into a pharmaceuticalC processor's dispensing area or cannabis dispensing facility.
Prior to the initial dispensing ofEcannabis products oil pursuant to each written certification, a pharmacist or pharmacy technician employed by the electronic means, for two years a paper or electronic copy of the written certification that provides an exact image of the document that is clearly legible;
and shall verify current board registration of the practitioner and the corresponding patient, registered agent, parent, or legal guardian if applicable.
and shall verify legal guardian if applicable.
Prior to any subsequent dispensing of current photo identification of the patient, registered agent, parent, or legal guardian and the current board registration issued to the patient, registered parent, or legal guardian if applicable.
Prior to any subsequent dispensing of cannabis oil pursuant to each written certification, an employee or delivery agent shall view a current photo identification of the patient, registered agent, or legal guardian and the current board registration processor or cannabis dispensing facility shall dispense more than a 90-day supply of a cannabiNcal product, as determined by the dispensing pharmacist or certifying practitioner, for any patient during any 90-day period;
No pharmaceutical processor or cannabis dispensing facility shall dispense more than a 90-day supply, of a cannabis product, as determined by the dispensing pharmacist or certifying practitioner, for any patient during any 90-day period.
however, a pharmaceutical processor or cannabis dispensing facility may dispenseAmore be dispensed for each 30-day period for which botanical cannabis is dispensed.
A pharmaceutical processor or cannabis dispensing facility may dispense less than a 90-day supply of a cannabis product for any patient during any 90-day period;
A pharmaceuticalbis shall processor or cannabis dispensing facility may dispense less than a 90-day supply.
however, a pharmaceutical processor or cannabis dispensing facility may dispense more than one cannabis product 30-day period for which botanical cannabis is dispensed.
In determining the appropriate amount of a cannabis product to be dispensed to a patient, a pharmaceutical processEr or cannabis dispensing facility shall consider all cannabis products dispensed to the patient and adjust the amoB.
A pharmaceutical processor or cannabis each dispensing facility may dispense less than a 90-day supply.
A pharmaceutical processor or cannabis dispensing facility shall dispense only cannabis products produced on the premises of a pharmaceutical processor permitted by the Board or cannabis oil that has been formulated with oil from industrial hemp acquired by a pharmaceutical processor from a registered industrial hemp dealer or processor pursuant to § 54.1-3442.6.
The Board shall establish in regulation an amount of cannabis oil that constitutes a 90-day supply to treat or alleviate the symptoms of a patient's diagnosed condition or disease.
A pharmaceutical processor may bUgin culC.
In determining the appropriate amount of a cannabis product to be dispensed to a patient, a pharmaceutical processor or cannabis dispensing facility shall consider all cannabis products dispensed to the patient and adjust the amount dispensed accordingly.
The Board shall report annually by December 1 to the Chairmen of the House Committee for B Health, Welfare and Institutions and the Senate Committee on Education and Health on the operatSon of pharmaceutical processors and cannabis dispensing facilities issued a permit by the Board, including the number of practitioners, patients, and registered agents, and parents or legal guardians of patTents who havD.
produced on the premises of a pharmaceutical processor permitted by the Board or cannabis oil that has been formulated with oil from industrial hemp acquired by a pharmaceutical processor from a registered industrial hemp dealer or processor pursuant to § 54.1-3442.6.
The concentration of delta-9-tetrahydrocannabinol in any cannabis product on site may be up to08.3.
A pharmaceutical processor may begin cultivation upon being issued a permit by the Board.
10 percent greater than or less than the level of delta-9-tetrahydrocannabinol measured for labTling.
C.
The Board shall report annually by December 1 to the Chairmen of the House Committee for Health, Welfare and Institutions and the Senate Committee on Education and Health on the operation of number of practitioners, patients, registered agents, and parents or legal guardians of patients who have registered with the Board and the number of written certifications issued pursuant to § 54.1-3408.3.
D.
The concentration of delta-9-tetrahydrocannabinol in any cannabis product on site may be up to 10 percent greater than or less than the level of delta-9-tetrahydrocannabinol measured for labeling.
T E B S 1
⬇ Download PDF
View plain text versions (2)

Action History

  1. Left in Health, Welfare and Institutions

  2. Assigned HWI sub: Subcommittee #3

  3. Referred to Committee on Health, Welfare and Institutions

  4. Read first time

  5. Placed on Calendar

  6. Impact statement from DPB (SB772S1)

  7. Passed Senate (40-Y 0-N)

  8. Constitutional reading dispensed (40-Y 0-N)

  9. Engrossed by Senate - committee substitute SB772S1

  10. Committee substitute agreed to 22106018D-S1

  11. Reading of substitute waived

  12. Read second time

  13. Constitutional reading dispensed (40-Y 0-N)

  14. Committee substitute printed 22106018D-S1

  15. Reported from Education and Health with substitute (15-Y 0-N)

  16. Impact statement from DPB (SB772)

  17. Senate subcommittee amendments and substitutes offered

  18. Assigned Education sub: Health Professions

  19. Referred to Committee on Education and Health

  20. Presented and ordered printed 22104985D

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 0 co-sponsors · 147 not signed on

Sponsors (1)

Co-sponsors (0)

None.

Not signed on (147)

147 members have not signed on to this bill.

Show all 147 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Votes

Passed Senate (40-Y 0-N)

Passed 40 Yea · 0 Nay
Party YeaNayPresentNot Voting
Unaffiliated 40000
Total 40000
% of votes cast 100%0%0%0%
How each member voted (40)
Member Party Vote
McClellan, Jennifer L. — Yea
Morrissey, Joseph D. — Yea
Spruill, Lionell, Sr. — Yea
Barbara A. Favola — Yea
Barker, George L. — Yea
Bell, John J. — Yea
Bill DeSteph — Yea
Bryce E. Reeves — Yea
Chase, Amanda F. — Yea
Cosgrove, John A., Jr. — Yea
David R. Suetterlein — Yea
David W. Marsden — Yea
Dunnavant, Siobhan S. — Yea
Ebbin, Adam P. — Yea
Edwards, John S. — Yea
Hanger, Emmett W., Jr. — Yea
Hashmi, Ghazala F. — Yea
Howell, Janet D. — Yea
Jennifer B. Boysko — Yea
Jeremy S. McPike — Yea
Kiggans, Jennifer A. — Yea
L. Louise Lucas — Yea
Lewis, Lynwood W., Jr. — Yea
Mamie E. Locke — Yea
Mark D. Obenshain — Yea
Mark J. Peake — Yea
Mason, T. Montgomery "Monty" — Yea
Newman, Stephen D. — Yea
Norment, Thomas K., Jr. — Yea
Petersen, J. Chapman — Yea
R. Creigh Deeds — Yea
Richard H. Stuart — Yea
Ruff, Frank M., Jr. — Yea
Ryan T. McDougle — Yea
Saslaw, Richard L. — Yea
Scott A. Surovell — Yea
T. Travis Hackworth — Yea
Todd E. Pillion — Yea
Vogel, Jill Holtzman — Yea
William M. Stanley, Jr. — Yea

Official roll call →

Constitutional reading dispensed (40-Y 0-N)

Passed 40 Yea · 0 Nay
Party YeaNayPresentNot Voting
Unaffiliated 40000
Total 40000
% of votes cast 100%0%0%0%
How each member voted (40)
Member Party Vote
McClellan, Jennifer L. — Yea
Morrissey, Joseph D. — Yea
Spruill, Lionell, Sr. — Yea
Barbara A. Favola — Yea
Barker, George L. — Yea
Bell, John J. — Yea
Bill DeSteph — Yea
Bryce E. Reeves — Yea
Chase, Amanda F. — Yea
Cosgrove, John A., Jr. — Yea
David R. Suetterlein — Yea
David W. Marsden — Yea
Dunnavant, Siobhan S. — Yea
Ebbin, Adam P. — Yea
Edwards, John S. — Yea
Hanger, Emmett W., Jr. — Yea
Hashmi, Ghazala F. — Yea
Howell, Janet D. — Yea
Jennifer B. Boysko — Yea
Jeremy S. McPike — Yea
Kiggans, Jennifer A. — Yea
L. Louise Lucas — Yea
Lewis, Lynwood W., Jr. — Yea
Mamie E. Locke — Yea
Mark D. Obenshain — Yea
Mark J. Peake — Yea
Mason, T. Montgomery "Monty" — Yea
Newman, Stephen D. — Yea
Norment, Thomas K., Jr. — Yea
Petersen, J. Chapman — Yea
R. Creigh Deeds — Yea
Richard H. Stuart — Yea
Ruff, Frank M., Jr. — Yea
Ryan T. McDougle — Yea
Saslaw, Richard L. — Yea
Scott A. Surovell — Yea
T. Travis Hackworth — Yea
Todd E. Pillion — Yea
Vogel, Jill Holtzman — Yea
William M. Stanley, Jr. — Yea

Official roll call →

Constitutional reading dispensed (40-Y 0-N)

Passed 40 Yea · 0 Nay
Party YeaNayPresentNot Voting
Unaffiliated 40000
Total 40000
% of votes cast 100%0%0%0%
How each member voted (40)
Member Party Vote
McClellan, Jennifer L. — Yea
Morrissey, Joseph D. — Yea
Spruill, Lionell, Sr. — Yea
Barbara A. Favola — Yea
Barker, George L. — Yea
Bell, John J. — Yea
Bill DeSteph — Yea
Bryce E. Reeves — Yea
Chase, Amanda F. — Yea
Cosgrove, John A., Jr. — Yea
David R. Suetterlein — Yea
David W. Marsden — Yea
Dunnavant, Siobhan S. — Yea
Ebbin, Adam P. — Yea
Edwards, John S. — Yea
Hanger, Emmett W., Jr. — Yea
Hashmi, Ghazala F. — Yea
Howell, Janet D. — Yea
Jennifer B. Boysko — Yea
Jeremy S. McPike — Yea
Kiggans, Jennifer A. — Yea
L. Louise Lucas — Yea
Lewis, Lynwood W., Jr. — Yea
Mamie E. Locke — Yea
Mark D. Obenshain — Yea
Mark J. Peake — Yea
Mason, T. Montgomery "Monty" — Yea
Newman, Stephen D. — Yea
Norment, Thomas K., Jr. — Yea
Petersen, J. Chapman — Yea
R. Creigh Deeds — Yea
Richard H. Stuart — Yea
Ruff, Frank M., Jr. — Yea
Ryan T. McDougle — Yea
Saslaw, Richard L. — Yea
Scott A. Surovell — Yea
T. Travis Hackworth — Yea
Todd E. Pillion — Yea
Vogel, Jill Holtzman — Yea
William M. Stanley, Jr. — Yea

Official roll call →

Reported from Education and Health with substitute (15-Y 0-N)

Passed 15 Yea · 0 Nay
Party YeaNayPresentNot Voting
Unaffiliated 15000
Total 15000
% of votes cast 100%0%0%0%
How each member voted (15)
Member Party Vote
Barker, George L. — Yea
Cosgrove, John A., Jr. — Yea
David R. Suetterlein — Yea
Dunnavant, Siobhan S. — Yea
Edwards, John S. — Yea
Hashmi, Ghazala F. — Yea
Howell, Janet D. — Yea
L. Louise Lucas — Yea
Lewis, Lynwood W., Jr. — Yea
Mamie E. Locke — Yea
Mark J. Peake — Yea
Newman, Stephen D. — Yea
Petersen, J. Chapman — Yea
Saslaw, Richard L. — Yea
Todd E. Pillion — Yea

Official roll call →

Subjects

public-safety healthcare
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does SB 772 do?
Board of Pharmacy; cannabis registration. Eliminates the Board of Pharmacy patient registration requirement for medical cannabis. The bill maintains the requirement that patients obtain a written certification from a health care provider to obtain medical cannabis.
Who sponsors SB 772?
SB 772 is sponsored by David W. Marsden.
What is the current status of SB 772?
This bill died with 2022 Regular Session. It reached “Passed Senate” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
Where can I track SB 772?
Track SB 772 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on SB 772

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of SB 772

Last checked for changes 3 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →